AI English summary of an SEC filing — figures as filed
DaVita DVAThe company said its operating cash flow was $2,059 million in 2023 and $1,565 million in 2022. It cited improved operating results, faster cash collections on accounts receivable and lower cash taxes paid as factors that increased cash flow, which it said were partially offset by higher interest payments.
Key points
AI summaryThe company said its operating cash flow was $2,059 million in 2023 and $1,565 million in 2022. It cited improved operating results, faster cash collections on accounts receivable and lower cash taxes paid as factors that increased cash flow, which it said were partially offset by higher interest payments.
The company said U.S. dialysis center closure costs were approximately $99.1 million in 2023, compared with approximately $85.7 million in 2022. It said it expects center closure levels in the next fiscal year to mirror the elevated closure levels of the current year.
The company said it repaid the remaining principal of its existing Term Loan A of $1,444 million and its existing revolving line of credit of $150 million in 2023. It said it refinanced the Term Loan A and the revolving line of credit with a secured Term Loan A-1 with total principal of $1,250 million.
The company said it repurchased 2,903,832 shares of common stock in 2023 and 8,094,661 shares in 2022. It said it repurchased 1,507,000 shares for $164 million from the end of 2023 through February 12, 2024.
Key figures
Fiscal year ended December 31, 2023
- Revenue
- $12.1B
- Operating income
- $1.6B
- Net income
- $692M
- EPS
- $7.42
- Operating cash flow
- $2.1B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Operating Cash Flow in 2023 $2,059 million
The company said its operating cash flow was $2,059 million in 2023 and $1,565 million in 2022. It cited improved operating results, faster cash collections on accounts receivable and lower cash taxes paid as factors that increased cash flow, which it said were partially offset by higher interest payments.
Source · Based on the MD&A text of the filing
U.S. Dialysis Center Closure Costs $99.1 million
The company said U.S. dialysis center closure costs were approximately $99.1 million in 2023, compared with approximately $85.7 million in 2022. It said it expects center closure levels in the next fiscal year to mirror the elevated closure levels of the current year.
Source · Based on the MD&A text of the filing
Debt Repayment and Term Loan A-1 Refinancing
The company said it repaid the remaining principal of its existing Term Loan A of $1,444 million and its existing revolving line of credit of $150 million in 2023. It said it refinanced the Term Loan A and the revolving line of credit with a secured Term Loan A-1 with total principal of $1,250 million.
Source · Based on the MD&A text of the filing
Share Repurchases of 2,903,832 Shares
The company said it repurchased 2,903,832 shares of common stock in 2023 and 8,094,661 shares in 2022. It said it repurchased 1,507,000 shares for $164 million from the end of 2023 through February 12, 2024.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…